Antibodies News and Research

RSS

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Researchers from Harvard Medical School and MIT have developed a new approach for identifying the "self" proteins targeted in autoimmune diseases such as multiple sclerosis, diabetes and rheumatoid arthritis.

3 Jun 2011

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

3 Jun 2011

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

MMRGlobal, Inc. and VisiInc PLC (VZJ) have entered into an agreement to launch MMRGlobal’s patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product. Initially, the two companies will collaborate on offering products and services jointly to the health technology market in Australia, which is currently projected to be as much as $2.4 billion this year.

2 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

Scientists develop carbohydrate-based vaccine against C. difficile infection

There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.

31 May 2011

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

Innovations in diagnosis and treatment for esophageal cancer

In recent years, the number of cases of adenocarcinoma of the esophagus (or gullet) has been on the rise. At the same time, however, new ways of treatment are improving the outlook for patients. In the current issue of Deutsches Ärzteblatt International, Angelika Behrens and her working group report on innovations in diagnosis and treatment.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Longer looks: Stem cells, vaccinating against addictive drugs, the GOP's budget hatchet man

Krista and Tatiana are not like most other sets of twins. They are connected at their heads, where their skulls merge under a mass of shaggy brown bangs. The girls run and play and go down their backyard slide, but whatever they do, they do together, their heads forever inclined toward each other's, their neck muscles strong and sinuous from a never-ending workout. Twins joined at the head — the medical term is craniopagus — are extremely rare.

27 May 2011

Bayer, Epitomics enter service agreement for antibody technology

Epitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany.

27 May 2011

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

A Brazilian hospital-based study assessed responses to flu vaccines in 340 RA patients in regular follow-up compared to 234 healthy patients.

26 May 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

26 May 2011

Study offers hope for reducing incidence of AIDS with potential preventive vaccine

The HIV epidemic is the largest in the world and represents one of the most serious public health problems, according to data from the World Health Organization. Only 30% of the more than 10 million patients in need have the access to the antiretroviral treatment.

24 May 2011

Analysis of Nubian-era mummies finds schistosomiasis spread from altering environment

Mummies from along the Nile are revealing how age-old irrigation techniques may have boosted the plague of schistosomiasis, a water-borne parasitic disease that infects an estimated 200 million people today.

24 May 2011

An alternative solid phase affinity matrix for chromatin immunoprecipitation

Porvair Filtration Group working in collaboration with the Department of Biological Sciences, University of Essex, UK has produced an alternative, high performance Solid Phase Affinity Matrix for Chromatin Immunoprecipitation (ChIP) assays. The research at Essex University evaluating the new BioVyon - Protein A material in ChIP assays is published in the May 2011 issue of Analytical Biochemistry.

From Chromatrap® - Porvair Sciences Ltd 23 May 2011

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference.

23 May 2011

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.

23 May 2011

Antibodies produced in space less effective than those produced on terra firma

The trip to Mars just got a little more difficult now that French researchers have discovered that antibodies used to fight off disease might become seriously compromised during long-term space flight. In a new report published online in the FASEB Journal, the scientists show that antibodies produced in space are less effective than those produced on terra firma.

21 May 2011

Antibodies News and Research

Cancer vaccine shows improved response rate in patients

New approach for identifying 'self' proteins targeted in autoimmune diseases

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

YM announces updates on nimotuzumab clinical development program

Scientists develop carbohydrate-based vaccine against C. difficile infection

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Innovations in diagnosis and treatment for esophageal cancer

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Longer looks: Stem cells, vaccinating against addictive drugs, the GOP's budget hatchet man

Bayer, Epitomics enter service agreement for antibody technology

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

Tofacitinib safe and effective for patients with rheumatoid arthritis

Study offers hope for reducing incidence of AIDS with potential preventive vaccine

Analysis of Nubian-era mummies finds schistosomiasis spread from altering environment

An alternative solid phase affinity matrix for chromatin immunoprecipitation

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Antibodies produced in space less effective than those produced on terra firma

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo